Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...
The Irish News on MSN13d
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
Armed robbery in Revesby5d
NHS Right to Deny Donanemab: Not Miracle Drug
There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer ...
News Medical on MSN10d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
MedPage Today on MSN7d
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An alternate dosing plan for the anti-amyloid ...
The Independent12d
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Your support makes all the difference. The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health ...